
Please try another search
Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer’s disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig’s disease. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.
Name | Age | Since | Title |
---|---|---|---|
Jon W. McGarity | 82 | 2024 | Independent Director |
Samuel M. Zentman | 79 | 2024 | Independent Director |
Robert S. Langer | 75 | 2024 | Member of Scientific Advisory Board |
D. Craig Willcox | - | - | Member of Scientific Advisory Board |
Michio Shimabukuro | - | - | Member of Scientific Advisory Board |
Bradley J. Willcox | - | - | Member of Scientific Advisory Board |
Richard Allsopp | - | - | Member of Scientific Advisory Board |
Makoto Kuro-O | - | 2024 | Member of Scientific Advisory Board |
Merit E. Cudkowicz | 61 | 2024 | Member of Scientific Advisory Board |
Riad Hussein El-Dada | 60 | 2024 | Independent Director |
Joseph Sinkule | 71 | 2024 | Founder, CEO, Chairman of the Board & Secretary |
Shalom Z. Hirschman | 89 | - | Medical Advisor & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review